Drug Trial Radar · NCT06216366
Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Aug 15, 2025
Primary completion
Sep 30, 2025
Study completion Nov 30, 2025
Sponsor
- Lead sponsor
- BioAegis Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Healthy trained SCUBA divers will be randomized into three groups and exposed to a high-pressure profile in a hyperbaric chamber. The high-pressure profile simulates the pressure at a depth of 30 meters of sea water (MSW) for 35 minutes. In the control group, the subjects will receive intravenous normal saline immediately before and after the high-pressure exposure. The second group will receive intravenous recombinant human gelsolin (rhu-pGSN) 24 mg/kg immediately prior to the exposure, and saline post-exposure. The third group will receive saline pre-exposure and rhu-pGSN post-exposure. Blood samples will be collected at multiple time points pre- and post-exposure to assess levels of inflammatory markers, including interleukin (IL)-1β. Other assessments include screening for gas bubbles, a validated questionnaire to assess the incidence of clinical decompression sickness (DCS), measurement of plasma gelsolin (pGSN) levels, and measurement of anti-pGSN antibodies.
Conditions
- Decompression Sickness
Interventions
Sodium Chloride 0.9% Inj pre-exposureDrug
Sterile normal saline 0.9% administered IV as a placebo immediately before hyperbaric chamber exposure
Sodium Chloride 0.9% Inj post-exposureDrug
Sterile normal saline 0.9% administered IV as a placebo immediately after hyperbaric chamber exposure
Recombinant human plasma gelsolin pre-exposureDrug
rhu-pGSN administered IV at a dose of 24 mg/kg immediately before hyperbaric chamber exposure
Recombinant human plasma gelsolin post-exposureDrug
rhu-pGSN administered IV at a dose of 24 mg/kg immediately after hyperbaric chamber exposure
Hyperbaric chamberOther
High-pressure profile equivalent 35 minutes at a depth of 30 meters of sea water
Primary outcomes
What the sponsor says the trial is designed to measure.
- Interleukin (IL)-1βTime frame: At baseline, during and after exposure, and afterward at 60, 120, and 240 minutes, at 24 hours, and at day 14
- Adverse EventsTime frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Maryland School of Medicine
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.